Vera Therapeutics Q3 product revenue $10.3 million; net loss widens to $93.7 million
Vera Therapeutics reported third quarter 2026 results, its first quarter with product revenue from TRUTAKNA, which received FDA accelerated approval on July 7, 2026. The company's net loss widened to $93.7 million, or $1.30 per share, from $80.3 million, or $1.26 per share, a year earlier, as selling, general and administrative expenses rose to $61.4 million to fund the launch.
Key points
- Net product revenue of $10.3 million in Q3 2026, compared with no product revenue in the prior-year period
- Net loss of $93.7 million, or $1.30 per share, versus $80.3 million, or $1.26 per share, in Q3 2025
- SG&A expenses of $61.4 million versus $27.5 million, reflecting commercial launch investment
- Cash, cash equivalents and marketable securities of $384.0 million at September 30, 2026; $75 million drawn from debt facility in October, with up to $350 million still available
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.